169 related articles for article (PubMed ID: 1376192)
1. Tumor markers in prostate cancer.
Cooper EH; Robinson MR; Whelan P; Ferro MA
Cancer; 1992 Jul; 70(1 Suppl):225-9. PubMed ID: 1376192
[TBL] [Abstract][Full Text] [Related]
2. Tumour markers in prostatic cancer.
Cooper EH
Scand J Clin Lab Invest Suppl; 1991; 206():42-51. PubMed ID: 1719610
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice.
Daver A; Soret JY; Coblentz Y; Allain YM; Cellier P; Chauveau P
Am J Clin Oncol; 1988; 11 Suppl 2():S53-60. PubMed ID: 2468273
[TBL] [Abstract][Full Text] [Related]
4. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
6. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.
Ercole CJ; Lange PH; Mathisen M; Chiou RK; Reddy PK; Vessella RL
J Urol; 1987 Nov; 138(5):1181-4. PubMed ID: 2444720
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases.
Wirth MP; Frohmüller HG
Eur Urol; 1992; 21(4):263-8. PubMed ID: 1281102
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
Turkes A; Nott J; Turkes AO; Griffiths K
Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
[TBL] [Abstract][Full Text] [Related]
11. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Emtage LA; Lewis PW; Blackledge GR
Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases.
Wirth MP; Frohmüller HG
Eur Urol; 1992; 22(1):27-32. PubMed ID: 1385142
[TBL] [Abstract][Full Text] [Related]
14. Is acid phosphatase (PAP) still justified in the management of prostatic cancer?
Kontturi M
Acta Oncol; 1991; 30(2):169-70. PubMed ID: 1709356
[TBL] [Abstract][Full Text] [Related]
15. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen in management of prostatic carcinoma.
Brawer MK; Lange PH
Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
Mulders TM; Bruning PF; Bonfrer JM
Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
Shinoda I
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
Zagars GK; Sherman NE; Babaian RJ
Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of prostate specific antigen in patients with prostate cancer.
Hudson MA; Bahnson RR; Catalona WJ
J Urol; 1989 Oct; 142(4):1011-7. PubMed ID: 2477559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
